A roundup of bio/pharmaceutical partnering news from GSK/Cambridge University and Bristol Myers Squibb/Evotec. 

* GSK, Cambridge University In $65-M Immune Disease Research Pact  
* Evotec, BMS Expand Molecular Glue Degrader Pact 

GSK, Cambridge University In $65-M Immune Disease Research Pact 
GSK has announced it is investing £50 million ($65 million) into a new five-year collaboration with the University of Cambridge and Cambridge University Hospitals in the UK to accelerate research and development into immune-related diseases.  

The collaboration builds on GSK’s and Cambridge University’s existing scientific relationship and will aim to find ways to more precisely treat immune-related disease with existing therapies, as well as develop new ones more rapidly. The collaboration will focus on two disease areas: respiratory and kidney.  

Source: GSK 

Evotec, BMS Expand Molecular Glue Degrader Pact 
Evotec and Bristol Myers Squibb (BMS) have expanded their pact relating to building a pipeline of molecular glue-degraders, a class of small molecules that help proteins or molecules within a cell interact, which can lead to the degradation of target proteins. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a program-based payment of $50 million from BMS to Evotec. 

Source: Evotec